Portfolio

HLEND seeks to build a diversified portfolio of senior secured private credit investments in resilient, market-leading, upper-middle market companies that operate primarily in non-cyclical sectors.

Data as of December 31, 2025

$25.3B

Investments at Fair Value

9.4%

Portfolio Yield at Fair Value1

93%

Private Investments2

96%

First Lien Exposure3

99%

Floating Rate4

$255M

Weighted Average EBITDA5

Portfolio Companies89

Clear Filters
Company Name
Industry
Investment Type
Reference Rate & Spread11
Par Amount (thousands)
Amortized Cost (thousands)
Fair Value (thousands)
% of Total Portfolio
BCPE Virginia Holdco, Inc. (Guidehouse Inc.) Professional Services Preferred Equity 13.75% Preferred Return $2,000 1,960 2,691 0.01%
Baker Tilly Advisory Group, LP (Baker Tilly) Professional Services 1st Lien Senior Secured Debt S + 4.50% $27,686 -297 -51 0.00%
Baker Tilly Advisory Group, LP (Baker Tilly) Professional Services 1st Lien Senior Secured Debt S + 4.75% $117,224 115,846 117,224 0.46%
Baker Tilly Advisory Group, LP (Baker Tilly) Professional Services 1st Lien Senior Secured Debt S + 4.25% $28,427 28,169 28,406 0.11%
Captive Resources Midco LLC (Captive Resources Midco, LLC) Professional Services 1st Lien Senior Secured Debt S + 4.50% $98,518 90,023 90,960 0.36%
Railpros Parent LLC Professional Services 1st Lien Senior Secured Debt S + 4.25% $28,602 24,510 24,808 0.10%
Sedgwick Claims Management Services Inc (Sedgwick) Professional Services 1st Lien Senior Secured Debt S + 2.50% $18,870 18,727 18,951 0.07%
Spirit RR Holdings, Inc. (Reorg Research) Professional Services 1st Lien Senior Secured Debt S + 4.50% $54,685 50,575 51,617 0.20%
YA Intermediate Holdings II LLC (Young and Associates) Professional Services 1st Lien Senior Secured Debt S + 5.00% $76,639 52,229 52,926 0.21%
Amneal Pharmaceuticals LLC (Amneal Pharmaceuticals) Pharmaceuticals 1st Lien Senior Secured Debt S + 3.50% $7,781 7,762 7,858 0.03%
Atlas Borrower, LLC (AnovoRx) Pharmaceuticals 1st Lien Senior Secured Debt S + 4.50% $103,467 87,245 87,395 0.34%
Azurity Pharmaceuticals Inc (Azurity Pharmaceuticals) Pharmaceuticals 1st Lien Senior Secured Debt S + 7.00% $251,960 227,190 220,729 0.87%
Creek Feeder, L.P. (Catalent Inc.) Pharmaceuticals Equity and other investments $9,000 9,000 9,751 0.04%
Creek Parent, Inc. (Catalent Inc.) Pharmaceuticals 1st Lien Senior Secured Debt S + 5.00% $142,618 118,254 119,674 0.47%
Creek Parent, Inc. (Catalent Inc.) Pharmaceuticals 1st Lien Senior Secured Debt S + 6.15% $1,210 1,193 1,205 0.00%
Dechra Finance US LLC (Dechra) Pharmaceuticals 1st Lien Senior Secured Debt S + 3.25% $4,135 4,126 4,171 0.02%
Endo Finance Holdings Inc (Endo) Pharmaceuticals 1st Lien Senior Secured Debt S + 3.75% $8,112 8,046 8,059 0.03%
Gusto Aus Bidco Pty Ltd (iNova Pharmaceuticals) Pharmaceuticals 1st Lien Senior Secured Debt B + 4.75% AUD 267,618 156,003 164,295 0.65%
MRO Maryruth LLC Personal Care Products 1st Lien Senior Secured Debt S + 4.75% $18,953 18,793 18,818 0.07%
MRO Maryruth LLC Personal Care Products 1st Lien Senior Secured Debt S + 4.00% $48,694 48,404 48,459 0.19%
Parfums Holding Company, Inc. (PDC Wellness) Personal Care Products 1st Lien Senior Secured Debt S + 5.25% $127,260 117,278 119,408 0.47%
CVR CHC LP (CVR Energy) Oil, Gas & Consumable Fuels 1st Lien Senior Secured Debt S + 4.00% $2,612 2,598 2,621 0.01%
ELNG Equity LLC (Eagle LNG Partners) Oil, Gas & Consumable Fuels Equity and other investments $109 - - 0.00%
Eagle LNG Partners Jacksonville II LLC (Eagle LNG Partners) Oil, Gas & Consumable Fuels 1st Lien Senior Secured Debt 13.50% (incl 6.35% PIK) $920 903 850 0.00%
Eagle LNG Partners Jacksonville II LLC (Eagle LNG Partners) Oil, Gas & Consumable Fuels Equity and other investments $0 0 - 0.00%

Engage with HLEND

Start Here

Footnotes

  1. Computed as (a) the annual stated interest rate or yield plus the annual accretion of discounts and less any annual amortization of premiums, as applicable, on accruing (i) debt and (ii) other income producing securities, divided by (b) total accruing (i) debt and (ii) other income producing securities (at fair value). Actual yields earned over the life of each investment could differ materially from the yields presented above. Please refer to HLEND’s prospectus and filings, including Form 10-Q or Form 10-K for fair value disclosures.
  2. Private Investments represents level 3 investments in the investment portfolio where inputs to the valuation methodology are unobservable and significant to overall fair value measurement. Private investments includes investments in joint ventures.
  3. Based on the aggregate fair value of the investment portfolio as of December 31, 2025.
  4. Percentage based on aggregate fair value of accruing debt.
  5. Calculated with respect to all level 3 investments (or, with respect to weighted average loan to value, all level 3 debt investments) in the investment portfolio for which fair value is determined by the Investment Adviser (in its capacity as the investment adviser of HLEND, with assistance, at least quarterly, from a third-party valuation firm, and overseen by HLEND’s Board of Trustees), and excludes quoted assets and investments in joint ventures. In the case of weighted average EBITDA only, excludes investments with no reported EBITDA or where EBITDA, in the Investment Adviser’s judgement made in its discretion, was not a material component of the original investment thesis, such as loan-to-value-based loans, NAV-based loans or reorganized equity. Weighted average EBITDA is weighted based on the fair value of the total applicable level 3 investments. Loan to value is calculated as net debt through each respective investment tranche in which HLEND holds an investment divided by enterprise value or value of underlying collateral of the portfolio company. Weighted average loan to value is weighted based on the fair value of the total applicable level 3 debt investments. Excludes investments on non-accrual status as of October 31, 2024. Figures are derived from the most recent financial statements from portfolio companies.
  6. Includes “last out” portions of first lien senior secured loans.
  7. Secured debt at the holding company level.
  8. Based on MSCI / S&P Global Industry Classification Standard (“GICS”) industry definition. Totals may not sum due to rounding. 
  9. All figures are as of December 31, 2025 unless otherwise indicated. % of total portfolio shown above is measured as total fair value of investments.
  10. Other includes structured finance investments.
  11. Contractual rates on preferred equity investments may represent preference accruals that are not recognized through investment income of the fund and as such are not included in the calculation of yield. The fair value of these investments may be influenced by the stated preference accrual or a minimum return threshold.